JPRN-UMIN000005819招募中2 期
Phase II clinical study of HLA-A*2402-restricted survivin-derived peptide vaccine therapy for patients with recurrent non-muscle-invasive bladder cancer - Phase II study of survivin-derived peptide vaccine therapy for patients with recurrent non-muscle-invasive bladder cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Coexistence of other malignancy 2) Immunodeficiency or history of splenectomy 3) Intake of steroids or immunosuppressants 4) Severe heart disease, active infection, coagulation disorder 5) Under anticoagulant therapy 6) Pregnant woman 7) Lactating woman 8) Hope to have a children 9) No willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures 10) History of severe drug allergy 11) History of severe drug-induced hepatic or renal dysfunction
研究者
相似试验
已完成
1 期
Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer.pancreatic cancerJPRN-UMIN000009881Sapporo Medical University9
已完成
1 期
Phase I/II clinical trial of HLA-A24 restricted epitope peptide cocktail therapy with UFT+LV for patients with advanced metastatic colorectal cancer.Advanced metastatic colorectal cancersJPRN-UMIN000007801Kinki University School of Medicine30
已完成
1 期
Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)Pancreatic CancerNCT00655785Fukushima Medical University17
已完成
1 期
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid TumorsSolid TumorsNCT01949688Shiga University26
Unknown
1 期
Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic CancerPancreatic CancerNCT00639925Fukushima Medical University5